Citigroup Issues Positive Forecast for Quest Diagnostics (NYSE:DGX) Stock Price

Quest Diagnostics (NYSE:DGX) had its price objective hoisted by investment analysts at Citigroup from $190.00 to $215.00 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has a “neutral” rating on the medical research company’s stock. Citigroup’s price target would suggest a potential upside of 5.39% from the company’s current price.

A number of other analysts have also issued reports on the stock. Weiss Ratings restated a “buy (b-)” rating on shares of Quest Diagnostics in a research report on Monday, December 29th. Truist Financial increased their price target on Quest Diagnostics from $195.00 to $205.00 and gave the stock a “hold” rating in a research note on Wednesday, October 22nd. Jefferies Financial Group lifted their price objective on Quest Diagnostics from $200.00 to $215.00 and gave the company a “buy” rating in a research report on Tuesday, October 21st. Wall Street Zen downgraded Quest Diagnostics from a “buy” rating to a “hold” rating in a research report on Sunday, January 25th. Finally, Mizuho lifted their price target on Quest Diagnostics from $190.00 to $210.00 and gave the company an “outperform” rating in a report on Friday, October 17th. Eight analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat, Quest Diagnostics has a consensus rating of “Moderate Buy” and a consensus price target of $200.64.

Quest Diagnostics Price Performance

Shares of NYSE:DGX traded up $12.75 on Tuesday, hitting $204.00. The company had a trading volume of 1,332,801 shares, compared to its average volume of 1,078,827. The company has a current ratio of 1.13, a quick ratio of 1.04 and a debt-to-equity ratio of 0.71. The company has a market cap of $22.69 billion, a PE ratio of 23.87, a PEG ratio of 2.41 and a beta of 0.66. Quest Diagnostics has a 52-week low of $157.20 and a 52-week high of $207.05. The business has a 50 day moving average of $181.33 and a 200 day moving average of $181.51.

Quest Diagnostics (NYSE:DGX) last announced its earnings results on Tuesday, February 10th. The medical research company reported $2.42 earnings per share for the quarter, beating the consensus estimate of $2.35 by $0.07. The firm had revenue of $2.81 billion during the quarter, compared to the consensus estimate of $2.75 billion. Quest Diagnostics had a net margin of 8.91% and a return on equity of 15.47%. The firm’s revenue for the quarter was up 7.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.23 EPS. Quest Diagnostics has set its FY 2026 guidance at 9.45-9.650 EPS. As a group, equities analysts anticipate that Quest Diagnostics will post 9.7 earnings per share for the current fiscal year.

Insider Transactions at Quest Diagnostics

In other news, Director Vicky B. Gregg sold 1,250 shares of the firm’s stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $191.76, for a total value of $239,700.00. Following the transaction, the director owned 17,037 shares of the company’s stock, valued at approximately $3,267,015.12. This trade represents a 6.84% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO J. E. Davis sold 55,093 shares of Quest Diagnostics stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $192.22, for a total transaction of $10,589,976.46. Following the transaction, the chief executive officer owned 120,480 shares in the company, valued at $23,158,665.60. The trade was a 31.38% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 64,289 shares of company stock worth $12,318,360. 8.16% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Quest Diagnostics

Large investors have recently modified their holdings of the stock. Lebenthal Global Advisors LLC increased its position in Quest Diagnostics by 117.5% during the third quarter. Lebenthal Global Advisors LLC now owns 5,034 shares of the medical research company’s stock worth $959,000 after acquiring an additional 2,720 shares during the period. Rakuten Investment Management Inc. acquired a new position in Quest Diagnostics in the 3rd quarter valued at $4,713,000. Pacer Advisors Inc. raised its stake in Quest Diagnostics by 2,531.6% in the third quarter. Pacer Advisors Inc. now owns 450,898 shares of the medical research company’s stock valued at $85,932,000 after purchasing an additional 433,764 shares in the last quarter. TKG Advisors LLC grew its stake in Quest Diagnostics by 125.1% during the third quarter. TKG Advisors LLC now owns 14,596 shares of the medical research company’s stock worth $2,782,000 after buying an additional 8,112 shares in the last quarter. Finally, Ethic Inc. increased its holdings in Quest Diagnostics by 144.2% in the 3rd quarter. Ethic Inc. now owns 14,424 shares of the medical research company’s stock valued at $2,749,000 after buying an additional 8,518 shares during the period. Institutional investors and hedge funds own 88.06% of the company’s stock.

Key Quest Diagnostics News

Here are the key news stories impacting Quest Diagnostics this week:

• Positive Sentiment: Q4 beats — Quest reported adjusted EPS of $2.42 vs. a $2.35 consensus and revenue of $2.81B (up 7.1% y/y); management cited stronger test volumes. This core beat and revenue growth are the primary catalyst for the stock lift. Quest Diagnostics’ Q4 Earnings & Revenues Beat Estimates, Stock Up
• Positive Sentiment: Shareholder returns boosted — Board increased the quarterly dividend 7.5% to $0.86 and authorized an additional $1.0B in share repurchases, which supports EPS and signals capital‑return commitment. Quest Diagnostics Increases Dividend 7.5% To $0.86 Per Quarter, Announces $1 Billion Repurchase
• Positive Sentiment: Full‑year 2025 results show strength — FY revenue rose ~11.8% to $11.04B, adjusted FY EPS up ~10.3%, and strong cash from operations ($1.89B), giving the company financial flexibility. Quest Diagnostics Reports Fourth Quarter and Full Year 2025 Financial Results
• Neutral Sentiment: Management forecasts sustained demand — Management highlighted continued lab test demand and provided FY2026 revenue guidance (roughly $11.70B–$11.82B) and profit outlook; Reuters notes the company is forecasting 2026 results above some Wall Street estimates, which supports the growth narrative but leaves details to be digested. Quest Diagnostics forecasts 2026 profit, revenue above estimates
• Negative Sentiment: FY2026 reported EPS guidance is conservative versus some street expectations — Quest gave reported EPS guidance of $9.45–$9.65 (adjusted EPS guidance was higher at $10.50–$10.70). The lower reported‑EPS range may temper upside versus prior analyst models and is a reason for mixed analyst reactions. Quest Diagnostics Reports Fourth Quarter and Full Year 2025 Financial Results

Quest Diagnostics Company Profile

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.